ANKHD1, ankyrin repeat and KH domain containing 1, is overexpressed in acute leukemias and is associated with SHP2 in K562 cells

Abstract

In the present study, increased levels of ANKHD1 mRNA and protein expression in leukemia cell lines are reported, as compared with normal hematopoietic cells. Furthermore, a higher expression of ANKHD1 mRNA was detected in primary acute leukemia samples than in normal hematopoietic cells (P=0.002). ANKHD1 was detected in the cytosolic and membrane fraction of cells and was co-immunoprecipitated with SHP2 in protein extracts of K562 and LNCaP cell lines. These findings suggest a role for ANKHD1 as a scaffolding protein that may be associated with the abnormal phenotype of leukemia cells.

Mask Is Required for the Activity of the Hippo Pathway Effector Yki/YAP

“…1C) [7, 10]. MASK1 is overexpressed in acute leukemia patient cells and cell lines [11] and regulates cell cycle progression and proliferation in multiple myeloma [12]. MASK2 is essential for vascular integrity during embryogenesis [13].…”

“…Additionally, MASK1 is over-expressed in acute leukemias [11] and regulates cell cycle progression and proliferation in multiple myeloma cells [12] suggesting that it may have oncogenic activity. To examine whether there is a relationship between clinical prognosis and expression of MASK1 in human cancers, we analyzed gene expression profiles of different breast cancer data sets using probes that identify the first ankyrin domain of MASK1 mRNA.…”

ANKHD1 (ankyrin repeat and KH domain containing 1)

“…In Drosophila, Mask acts in the signal transduction pathway mediated by Cws (Corkscrew; orthologous of SHP2) (Smith, et al, 2002), participates in the Hippo signaling pathway activation through its association with Yki (Yorkie, orthologous of YAP1) (Sidor, et al, 2013, SansoresGarcia, et al, 2013 and potentially regulates Hop signaling pathway (Hopscotch, orthologous of JAK) (Muller, et al, 2005). In humans, ANKHD1 associates with SHP2, however the biologic consequence of this protein interaction remains indeterminate (Traina, et al, 2006). ANKHD1 and YAP1 interaction has also been confirmed in human cells (HEK293 and DU145 cells) and modulates the Hippo signaling pathway activation, proliferation and cell cycle progression (Sidor, et al, 2013, Sansores-Garcia, et al, 2013, Machado-Neto, et al, 2014.…”

“…Leukemia Note ANKHD1 was reported as highly expressed in leukemia cell lines and in primary bone marrow samples from patients with acute myeloid leukemia and acute lymphoid leukemia (Traina, et al, 2006). Interestingly, ANKHD1 silencing reduced cell proliferation, clonogenicity, migration and tumorigenesis of leukemia cells .…”

Hippo pathway deregulation: implications in the pathogenesis of haematological malignancies

“…In ALL and AML, the leukaemic cells display increased expression levels of ANKHD1, a scaffolding protein related to a phenotypic defect, and leukaemia cell proliferation that is required for full activation of YAP 62. The multiple myeloma patient cells and myeloma cell lines also express high levels of the ANKHD1 protein, whose silencing promotes cell cycle arrest in S phase and inhibition of cell growth without affecting the rate of apoptosis 63…”